Numerous clinical trials evaluate tirzepatide across early to late clinical phases, focusing primarily on metabolic and endocrine conditions such as type 2 diabetes mellitus, obesity, binge eating disorder, and metabolic syndrome. Sponsored by pharmaceutical leaders including Eli Lilly and Company alongside academic institutions like Johns Hopkins University and the Pennington Biomedical Research Center, these studies range from active recruitment to completed statuses. These investigations evaluate critical outcomes including glycemic efficacy, therapeutic switching, and alterations in eating behaviors.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07559500 | RECRUITING | Alcohol Use Disorder (AUD) |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
2026-05-20 | PHASE1 |
| NCT07165028 | RECRUITING | Metabolic Dysfunction-Associated Steatotic Liver Disease |
Eli Lilly and Company |
2025-10-15 | PHASE3 |
| NCT07782359 | NOT_YET_RECRUITING | Lung Cancer |
University of Chicago |
2026-10 | PHASE1 |
| NCT07527910 | RECRUITING | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
Regeneron Pharmaceuticals |
2026-05-22 | PHASE2 |
| NCT07693608 | ENROLLING_BY_INVITATION | Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders |
University of Texas Southwestern Medical Center |
2026-08-19 | PHASE2 |
| NCT07349641 | NOT_YET_RECRUITING | Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma |
National Cancer Institute (NCI) |
2026-11-01 | PHASE2 |
| NCT07715929 | NOT_YET_RECRUITING | Atrial Fibrillation; Obesity & Overweight; Catheter Ablation |
Yunlong Wang |
2026-09-01 | PHASE4 |
| NCT07091734 | RECRUITING | Lipodystrophy, Partial |
University of Michigan |
2025-09-08 | PHASE2 |
| NCT06517212 | RECRUITING | Breast Cancer; Breast Neoplasms; Breast Cancers |
Baylor Research Institute |
2024-11-26 | PHASE2 |
| NCT06885736 | RECRUITING | Obesity |
Dasman Diabetes Institute |
2025-08-07 | |
| NCT07630454 | NOT_YET_RECRUITING | Atrial Fibrillation; Heart Failure With Preserved Ejection Fraction (HFpEF); Tirzepatide |
Yunlong Wang |
2026-08-01 | PHASE4 |
| NCT07635953 | NOT_YET_RECRUITING | Diabetes Mellitus |
Sun Yat-sen University |
2026-07-01 | PHASE3 |
| NCT07247084 | RECRUITING | Obesity |
Eli Lilly and Company |
2025-11-24 | PHASE4 |
| NCT06582875 | RECRUITING | Autosomal Dominant Polycystic Kidney; Obesity |
University of Colorado, Denver |
2025-03-06 | PHASE2 |
| NCT07574723 | RECRUITING | Obesity |
Dasman Diabetes Institute |
2026-05-15 | |
| NCT06246799 | RECRUITING | Type 2 Diabetes (Adult Onset) |
The University of Texas Health Science Center at San Antonio |
2024-11-07 | PHASE3 |
| NCT07554638 | RECRUITING | Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Obesity |
Columbia University |
2026-08-07 | PHASE4 |
| NCT07078838 | NOT_YET_RECRUITING | Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma |
UNC Lineberger Comprehensive Cancer Center |
2026-08 | PHASE2 |
| NCT05933499 | RECRUITING | Obesity |
Massachusetts General Hospital |
2025-11-05 | PHASE2 |
| NCT07326111 | RECRUITING | Polycystic Ovary Syndrome (PCOS); Obesity & Overweight |
University of Bonn |
2025-12-09 | PHASE4 |
| NCT06180616 | NOT_YET_RECRUITING | Type 1 Diabetes Mellitus; Overweight and Obesity |
Royal North Shore Hospital |
2026-12 | PHASE2 |
| NCT07555730 | NOT_YET_RECRUITING | Overweight or Obesity; Type 2 Diabetes; Weight Loss Maintenance |
Huazhong University of Science and Technology |
2026-04-30 | PHASE4 |
| NCT07589322 | RECRUITING | Obesity and Metabolic Syndrome |
Tri-Service General Hospital (TSGH) |
2026-03-31 | |
| NCT07747805 | NOT_YET_RECRUITING | COPD; Obesity & Overweight; Sarcopenia |
The Cleveland Clinic |
2026-08-28 | PHASE2 |
| NCT06939088 | RECRUITING | Alcohol Use Disorder; Alcohol Abuse/Dependence; Alcohol Dependence; Alcoholism; Schizophrenia Disorders; Schizophrenia and Disorders With Psychotic Features; Schizophrenia and Schizophrenia Spectrum Psychosis; Schizophrenia |
Anders Fink-Jensen, MD, DMSci |
2025-05-05 | PHASE2 |
| NCT07573163 | RECRUITING | Mild Autonomous Cortisol Secretion (MACS); Adrenalectomy; Status |
Alaa Sada |
2026-07-27 | PHASE2 |
| NCT07671248 | NOT_YET_RECRUITING | Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe |
McMaster University |
2026-08-01 | PHASE3 |
| NCT07706088 | NOT_YET_RECRUITING | Neuropathy, Small Fiber; Diabete Mellitus |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2026-07 | PHASE4 |
| NCT07065552 | RECRUITING | Endometrial Cancer; Obesity |
UNC Lineberger Comprehensive Cancer Center |
2026-04-27 | EARLY_PHASE1 |
| NCT07265752 | NOT_YET_RECRUITING | Cannabis Use Disorder |
Brigham and Women's Hospital |
2026-07-01 | PHASE2 |
| NCT05912621 | RECRUITING | Obesity; Overweight and Obesity; Overweight |
Stanford University |
2023-11-09 | PHASE2 |
| NCT07734792 | NOT_YET_RECRUITING | Acute Ischemic Stroke (AIS) |
yifang zhu |
2026-08-10 | PHASE2; PHASE3 |
| NCT07734870 | NOT_YET_RECRUITING | Central Centrifugal Cicatricial Alopecia (CCCA) |
Johns Hopkins University |
2026-09-15 | PHASE2 |
| NCT07633639 | RECRUITING | Obesity |
China-Japan Friendship Hospital |
2026-05-01 | |
| NCT06976853 | RECRUITING | Crohn Disease (CD) |
Washington University School of Medicine |
2025-05-13 | PHASE2 |
| NCT06937099 | RECRUITING | Crohn's Disease; Obesity or Overweight |
Eli Lilly and Company |
2025-06-26 | PHASE3 |
| NCT06857942 | RECRUITING | Psoriasis; Overweight or Obesity |
Eli Lilly and Company |
2025-03-19 | PHASE4 |
| NCT07202247 | RECRUITING | Prostate Carcinoma; Recurrent Prostate Carcinoma |
City of Hope Medical Center |
2025-11-05 | PHASE2 |
| NCT06937086 | RECRUITING | Ulcerative Colitis; Obesity or Overweight |
Eli Lilly and Company |
2025-06-26 | PHASE3 |
| NCT07468552 | NOT_YET_RECRUITING | Cannabis Use Disorder |
National Institute on Drug Abuse (NIDA) |
2026-11-15 | PHASE2 |
| NCT07676331 | NOT_YET_RECRUITING | Hormone-receptor-positive Breast Cancer; Early Breast Cancer |
Universitaire Ziekenhuizen KU Leuven |
2026-08-01 | PHASE2 |
| NCT07602699 | RECRUITING | Smoking Cessation; Smoking Behaviors |
University of Southern California |
2026-06-05 | PHASE2 |
| NCT07096908 | RECRUITING | Type1diabetes; Obesity |
Dasman Diabetes Institute |
2025-07-31 | PHASE4 |
| NCT07387796 | RECRUITING | Drug Discontinuation; Substance Use Disorders; Eating Behavior Changes; Tirzepatide |
The University of Texas at Dallas |
2026-10 | |
| NCT07443956 | RECRUITING | Psoriatic Arthritis (PsA); Obesity & Overweight |
NHS Greater Glasgow and Clyde |
2026-03-09 | |
| NCT06801015 | ACTIVE_NOT_RECRUITING | Obesity |
Mayo Clinic |
2025-10-01 | PHASE4 |
| NCT07284511 | RECRUITING | Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2026-05-19 | PHASE2; PHASE3 |
| NCT07605247 | NOT_YET_RECRUITING | Endometrial Cancer |
Rutgers, The State University of New Jersey |
2026-06-01 | PHASE2 |
| NCT06820281 | RECRUITING | Type 1 Diabetes Mellitus |
Victor Chang Cardiac Research Institute |
2026-07-07 | PHASE2 |
| NCT07382024 | NOT_YET_RECRUITING | Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight |
National Taiwan University Hospital |
2026-06-16 | |
| NCT06657209 | RECRUITING | Diabetes Mellitus, Type 2; Diabetes; Type 2 Diabetes; Pre Diabetes |
Stanford University |
2025-01-13 | PHASE4 |
| NCT07257484 | RECRUITING | Obesity (Disorder); Breast Cancer |
Weill Medical College of Cornell University |
2026-06-08 | PHASE4 |
| NCT06847399 | RECRUITING | Obesity and Overweight; Binge Eating Disorder |
Johns Hopkins University |
2025-09-17 | PHASE2 |
| NCT07457437 | RECRUITING | Muscle Mass and Strength; Obesity & Overweight; Physical Function |
University of Exeter |
2026-04-01 | |
| NCT06751589 | RECRUITING | Endometrial Cancer |
Memorial Sloan Kettering Cancer Center |
2024-12-19 | EARLY_PHASE1 |
| NCT07707778 | ENROLLING_BY_INVITATION | Human Immunodeficiency Virus (HIV); Metabolic Dysfunction Associated Steatotic Liver Disease; Dyslipidaemia; Diabetes Mellitus; Obesity & Overweight; Metabolic Syndrome |
National Taiwan University Clinical Trial Center |
2026-06-25 | PHASE4 |
| NCT07228741 | RECRUITING | Acute Lymphoblastic Leukemia; Obesity |
St. Jude Children's Research Hospital |
2026-04-23 | PHASE2 |
| NCT07220473 | RECRUITING | Aging; LONGEVITY 1 |
The University of Texas Medical Branch, Galveston |
2026-02-27 | PHASE2 |
| NCT06864026 | RECRUITING | Psoriatic Arthritis; Overweight or Obesity |
Eli Lilly and Company |
2025-03-06 | PHASE4 |
| NCT07697391 | NOT_YET_RECRUITING | Obesity; Diabetes Mellitus, Type 2 |
The First Affiliated Hospital of Anhui Medical University |
2026-07-20 | PHASE4 |
| NCT06439277 | RECRUITING | Obesity; Weight Gain |
Eli Lilly and Company |
2024-06-03 | PHASE3 |
| NCT05556512 | ACTIVE_NOT_RECRUITING | Obesity; Overweight |
Eli Lilly and Company |
2022-10-11 | PHASE3 |
| NCT06518837 | RECRUITING | Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer |
Rutgers, The State University of New Jersey |
2024-10-30 | PHASE2 |
| NCT06651177 | RECRUITING | Opioid Use Disorder; Opioid Use Disorder, Moderate; Opioid Use Disorder, Severe |
T. John Winhusen, PhD |
2026-01-29 | PHASE2 |
| NCT07796477 | NOT_YET_RECRUITING | T2DM (Type 2 Diabetes Mellitus) |
CSPC Ouyi Pharmaceutical Co., Ltd. |
2026-11-06 | PHASE2 |
| NCT07218445 | RECRUITING | Obesity; Menopause Hot Flashes |
Mayo Clinic |
2026-04-08 | PHASE4 |
| NCT06700538 | RECRUITING | Obesity |
Arrowhead Pharmaceuticals |
2024-12-04 | PHASE1; PHASE2 |
| NCT06575738 | RECRUITING | Obesity; Adolescent Obesity; Body-Weight Trajectory; Weight Loss Trajectory; Bariatric Surgery; Anti-obesity Agents |
University of Colorado, Denver |
2024-10-11 | PHASE1 |
| NCT06734273 | RECRUITING | Obesity and Obesity-related Medical Conditions |
Nicholas Skertich |
2025-03-10 | EARLY_PHASE1 |
| NCT06143956 | RECRUITING | Obesity; Overweight |
Eli Lilly and Company |
2023-11-17 | PHASE2 |
| NCT07756359 | NOT_YET_RECRUITING | Pouch, Ileal; Pouches, Ileoanal; Bowel Diseases, Inflammatory |
University of North Carolina, Chapel Hill |
2026-09 | PHASE4 |
| NCT06732245 | NOT_YET_RECRUITING | Obesity and Overweight |
Biomed Industries, Inc. |
2026-08-15 | PHASE2 |
| NCT07588438 | RECRUITING | Obesity; Diabetes Mellitus, Type 2 |
Las Rías Medical Center |
2026-07-27 | PHASE4 |
| NCT07191873 | RECRUITING | Idiopathic Intracranial Hypertension (IIH) |
Duke University |
2026-08-25 | PHASE4 |
| NCT07046819 | RECRUITING | Metabolic Alcohol-associated Liver Disease; Alcohol Use Disorder |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
2026-06-11 | PHASE2 |
| NCT06803888 | ACTIVE_NOT_RECRUITING | Obesity and Obesity-related Medical Conditions |
Ali Aminian |
2025-01-29 | PHASE4 |
| NCT07438444 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus, Type 2; Obesity; Overweight |
Eli Lilly and Company |
2026-02-27 | PHASE4 |
| NCT07671391 | NOT_YET_RECRUITING | Obesity Adult Onset |
Shanghai Zhongshan Hospital |
2026-08 | PHASE2 |
| NCT07354880 | NOT_YET_RECRUITING | Obesity & Overweight; Adult Congenital Heart Disease |
University Medical Centre Ljubljana |
2026-01-20 | PHASE4 |
| NCT07738276 | NOT_YET_RECRUITING | Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide |
Shahid Beheshti University of Medical Sciences |
2026-07-18 | PHASE3 |
| NCT07777575 | NOT_YET_RECRUITING | Obesity (BMI>30) |
Technical University of Munich |
2026-08-17 | PHASE4 |
| NCT07292519 | NOT_YET_RECRUITING | Alcohol Use Disorder (AUD); Overweight or Obese; Comorbidities and Coexisting Conditions |
South West Sydney Local Health District |
2026-01-15 | PHASE2 |
| NCT06191848 | RECRUITING | Obesity; Knee Osteoarthritis; Osteoarthritis, Knee |
University of Melbourne |
2024-11-19 | PHASE4 |
| NCT07463846 | RECRUITING | Obesity |
Alnylam Pharmaceuticals |
2026-03-02 | PHASE1; PHASE2 |
| NCT07293325 | RECRUITING | Adults With Simple Obesity |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2025-06-02 | |
| NCT06811324 | RECRUITING | Obesity Prevention; Sarcopenia in Elderly; Cardiovascular Function; GLP - 1; Weight Loss |
The University of Texas Health Science Center at San Antonio |
2026-04-01 | PHASE2 |
| NCT07483801 | NOT_YET_RECRUITING | Cardiovascular Diseases |
Cambridge University Hospitals NHS Foundation Trust |
2026-03 | PHASE4 |
| NCT07095517 | RECRUITING | Colorectal Cancer Prevention; Colorectal Adenoma |
Massachusetts General Hospital |
2026-02-24 | PHASE1 |
| NCT06606821 | RECRUITING | Coronary Artery Disease; Coronary Microvascular Dysfunction; Overweight or Obesity; Stable Angina Pectoris; Chronic Coronary Artery Disease; Atherosclerosis Cardiovascular Disease |
Tina Vilsbøll |
2024-10-01 | PHASE4 |
| NCT06774079 | RECRUITING | Crohn Disease |
University of Miami |
2025-03-05 | PHASE4 |
| NCT07685834 | ACTIVE_NOT_RECRUITING | Lax Skin |
Sofwave Medical LTD |
2026-02-27 | |
| NCT06727331 | RECRUITING | Alcohol Use Disorder (AUD) |
Brigham and Women's Hospital |
2025-09-15 | PHASE2 |
| NCT07245771 | RECRUITING | Obesity &Amp; Overweight |
Ikaria Bioscience Pty Ltd |
2025-11-04 | PHASE1; PHASE2 |
| NCT06484114 | ACTIVE_NOT_RECRUITING | Obesity; Weight Change Trajectory; Weight Change, Body |
Fractyl Health Inc. |
2024-09-01 | |
| NCT07481747 | RECRUITING | Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities |
Hudson Biotech |
2026-02-02 | PHASE3 |
| NCT07521631 | RECRUITING | Obesity |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2026-03-31 | PHASE2 |
| NCT07154719 | RECRUITING | Musculoskeletal Abnormalities; Obesity; Sarcopenic Obesity; Osteoporosis; Drug Effect |
Pennington Biomedical Research Center |
2025-10-09 | PHASE4 |
| NCT07728318 | NOT_YET_RECRUITING | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight |
Akhtar Saeed Medical and Dental College |
2026-08-12 | |
| NCT06162715 | ACTIVE_NOT_RECRUITING | Severe Obesity; Obesity; BMI Greater Than 30 |
Vanderbilt University Medical Center |
2024-10-30 | PHASE2; PHASE3 |
| NCT07364175 | RECRUITING | Hypertension; Obesity & Overweight |
Cambridge University Hospitals NHS Foundation Trust |
2026-01 | |
| NCT06802081 | RECRUITING | Atrial Fibrillation; Obesity |
The Cleveland Clinic |
2025-04-08 | PHASE2 |
| NCT06759701 | RECRUITING | Diabetes; Prostate Cancer |
M.D. Anderson Cancer Center |
2025-07-02 | EARLY_PHASE1 |
| NCT06721507 | RECRUITING | Obesity and Obesity-related Medical Conditions; Bariatric Surgery |
Marlene Starr |
2025-03-27 | PHASE4 |
| NCT07057310 | ENROLLING_BY_INVITATION | Obesity; Menopause |
Mayo Clinic |
2025-05-01 | PHASE4 |
| NCT07803744 | NOT_YET_RECRUITING | Diabetes Mellitus, Type 1; Overweight; Obesity |
Eli Lilly and Company |
2026-09 | PHASE1 |
| NCT07298915 | NOT_YET_RECRUITING | Obesity & Overweight |
University of Virginia |
2026-08 | PHASE3 |
| NCT07373834 | RECRUITING | Obesity (Disorder) |
University Medical Centre Ljubljana |
2026-01 | |
| NCT07128082 | ACTIVE_NOT_RECRUITING | Long COVID |
Scripps Translational Science Institute |
2025-10-30 | PHASE2 |
| NCT06897475 | RECRUITING | Type 2 Diabetes |
Eli Lilly and Company |
2025-03-28 | PHASE2 |
| NCT07740291 | RECRUITING | Obesity & Overweight; Cardiometabolic Health Indicators; Addiction; Eating Disorders; Mental Health |
Texas Tech University |
2025-01-02 | |
| NCT06962280 | ACTIVE_NOT_RECRUITING | Type 1 Diabetes; Obesity; Overweight |
Eli Lilly and Company |
2025-05-12 | PHASE3 |
| NCT06662383 | ACTIVE_NOT_RECRUITING | Obesity |
Eli Lilly and Company |
2024-11-01 | PHASE3 |
| NCT06914895 | ACTIVE_NOT_RECRUITING | Type 1 Diabetes; Obesity; Overweight |
Eli Lilly and Company |
2025-04-25 | PHASE3 |
| NCT07299084 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus, Type 2; Overweight; Obesity |
Eli Lilly and Company |
2026-01-14 | PHASE1 |
| NCT07319975 | NOT_YET_RECRUITING | Obesity |
Istanbul Galata University |
2025-12-29 | |
| NCT06934642 | RECRUITING | MASLD; Obesity |
University of New Mexico |
2025-06-30 | EARLY_PHASE1 |
| NCT06861439 | ACTIVE_NOT_RECRUITING | Obesity |
Wake Forest University Health Sciences |
2025-07-07 | PHASE4 |
| NCT07000955 | ACTIVE_NOT_RECRUITING | Obesity |
Innovent Biologics (Suzhou) Co. Ltd. |
2025-06-17 | PHASE1; PHASE2 |
| NCT05536804 | ACTIVE_NOT_RECRUITING | Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D |
Eli Lilly and Company |
2023-02-08 | PHASE2 |
| NCT05822544 | ACTIVE_NOT_RECRUITING | Healthy Subjects; Obesity; Type 2 Diabetes |
OrsoBio, Inc |
2023-04-22 | PHASE1 |
| NCT06994338 | RECRUITING | Alcohol Use Disorder; Obesity and Overweight; Alcohol |
University of Southern California |
2025-10-06 | PHASE2 |
| NCT06965413 | ACTIVE_NOT_RECRUITING | Obesity; Overweight; Overweight With One Weight Related Comorbidity |
Hoffmann-La Roche |
2025-05-05 | PHASE2 |
| NCT07179120 | NOT_YET_RECRUITING | Obesity-related Male Infertility |
First Affiliated Hospital of Wenzhou Medical University |
2026-05-01 | PHASE2 |
| NCT06603571 | ACTIVE_NOT_RECRUITING | Obesity; Overweight |
Eli Lilly and Company |
2024-09-20 | PHASE2 |
| NCT07423247 | RECRUITING | Tirzepatide |
Shahid Beheshti University of Medical Sciences |
2026-01-01 | PHASE4 |
| NCT06918405 | ACTIVE_NOT_RECRUITING | Obesity and Obesity-related Medical Conditions |
Chittagong Medical College |
2025-01-01 | PHASE3 |
| NCT06935838 | COMPLETED | Obesity and Overweight; HIV; Chronic Inflammation |
University of Hawaii |
2025-11-12 | PHASE2 |
| NCT06075667 | ACTIVE_NOT_RECRUITING | Obesity; Overweight |
Eli Lilly and Company |
2023-10-16 | PHASE3 |
| NCT06534411 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2024-11-05 | PHASE3 |
| NCT06901245 | RECRUITING | Prader-Willi Syndrome; Hypothalamic Obesity; Obesity/Therapy |
Grace Kim |
2025-05-01 | PHASE4 |
| NCT06630585 | RECRUITING | Type 1 Diabetes (T1D) |
University of Bern |
2025-02-14 | PHASE3 |
| NCT06635057 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2024-10-11 | PHASE4 |
| NCT07176663 | NOT_YET_RECRUITING | Obesity |
Shahid Beheshti University of Medical Sciences |
2026-02-01 | |
| NCT06745128 | ACTIVE_NOT_RECRUITING | Obesity; Methamphetamine Use Disorder |
University of Texas Southwestern Medical Center |
2025-02-03 | PHASE2 |
| NCT06221969 | COMPLETED | Type 2 Diabetes |
Novo Nordisk A/S |
2024-01-16 | PHASE3 |
| NCT06737042 | COMPLETED | Obesity and Overweight |
Gan and Lee Pharmaceuticals, USA |
2025-02-24 | PHASE2 |
| NCT06605703 | COMPLETED | Obesity; Overweight |
WW International Inc |
2024-09-18 | PHASE4 |
| NCT06047548 | COMPLETED | Overweight; Obesity |
Eli Lilly and Company |
2023-09-20 | PHASE3 |
| NCT06916065 | COMPLETED | Overweight; Obesity |
Eli Lilly and Company |
2025-04-09 | PHASE1 |
| NCT06643728 | ACTIVE_NOT_RECRUITING | Obesity; Overweight |
Eli Lilly and Company |
2024-10-21 | PHASE2 |
| NCT06911203 | RECRUITING | Obesity |
BrightGene Bio-Medical Technology Co., Ltd. |
2025-04-03 | PHASE2 |
| NCT06588283 | COMPLETED | Psoriasis; Obesity |
Eli Lilly and Company |
2024-09-30 | PHASE3 |
| NCT06037252 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes; Obesity |
Eli Lilly and Company |
2023-09-21 | PHASE2 |
| NCT06373146 | COMPLETED | Obesity |
Eli Lilly and Company |
2024-04-24 | PHASE2 |
| NCT06131437 | COMPLETED | Obesity |
Novo Nordisk A/S |
2023-11-27 | PHASE3 |
| NCT05708859 | RECRUITING | Type II Diabetes; Atherosclerosis |
Matthew J. Budoff |
2024-01-02 | PHASE4 |
| NCT06893211 | COMPLETED | Obesity |
University Medical Centre Ljubljana |
2025-03-18 | PHASE2 |
| NCT06297616 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2024-04-15 | PHASE1 |
| NCT06588296 | COMPLETED | Psoriatic Arthritis; Obesity |
Eli Lilly and Company |
2024-09-24 | PHASE3 |
| NCT05433584 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes |
Eli Lilly and Company |
2022-08-01 | PHASE4 |
| NCT06345066 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2024-04-03 | PHASE1 |
| NCT06890611 | COMPLETED | Healthy |
Eli Lilly and Company |
2025-03-25 | PHASE1 |
| NCT06648031 | COMPLETED | Type2diabetes |
Lexaria Bioscience Corp. |
2024-12-04 | PHASE1 |
| NCT07303556 | ACTIVE_NOT_RECRUITING | Heart Failure; Diabete Type 2; Arterial Hypertension |
Nazarbayev University |
2024-12-18 | |
| NCT04255433 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2020-05-29 | PHASE3 |
| NCT06901349 | WITHDRAWN | Obesity; Overweight |
Eli Lilly and Company |
2025-05-23 | PHASE2 |
| NCT06326060 | COMPLETED | Obesity |
Novo Nordisk A/S |
2024-03-18 | PHASE2 |
| NCT06301256 | UNKNOWN | Hidradenitis Suppurativa |
Florida Academic Centers Research and Education, LLC |
2024-03-11 | |
| NCT06445075 | COMPLETED | Overweight and Obesity |
Scholar Rock, Inc. |
2024-05-21 | PHASE2 |
| NCT06515418 | TERMINATED | Obesity |
BioAge Labs, Inc. |
2024-06-27 | PHASE2 |
| NCT06565611 | ACTIVE_NOT_RECRUITING | Obesity |
Palatin Technologies, Inc |
2024-08-05 | PHASE2 |
| NCT05696847 | COMPLETED | Obesity |
Eli Lilly and Company |
2023-02-07 | PHASE1 |
| NCT06640972 | COMPLETED | Triglycerides; Weight Gain Trajectory; Cholesterol, Elevated |
Response Pharmaceuticals |
2024-09-27 | PHASE2 |
| NCT06400615 | COMPLETED | OSA |
Apnimed |
2024-05-20 | PHASE2 |
| NCT05822830 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2023-04-21 | PHASE3 |
| NCT05963022 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2023-08-21 | PHASE3 |
| NCT05659368 | UNKNOWN | Wolfram Syndrome |
Ospedale San Raffaele |
2024-01-01 | PHASE2 |
| NCT05260021 | COMPLETED | Type2 Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; T2D; T2DM (Type 2 Diabetes Mellitus); Glucose Metabolism Disorders; Endocrine System Diseases; Metabolic Disease |
Eli Lilly and Company |
2022-04-13 | PHASE3 |
| NCT05564039 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2022-11-30 | PHASE4 |
| NCT04847557 | COMPLETED | Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF) |
Eli Lilly and Company |
2021-04-20 | PHASE3 |
| NCT05691712 | COMPLETED | Diabetes Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases |
Eli Lilly and Company |
2023-02-05 | PHASE3 |
| NCT06009653 | WITHDRAWN | Obesity; Metabolic Disease |
Washington University School of Medicine |
2023-09-13 | PHASE4 |
| NCT05412004 | COMPLETED | Obstructive Sleep Apnea; Obesity |
Eli Lilly and Company |
2022-06-21 | PHASE3 |
| NCT05978713 | COMPLETED | Healthy |
Eli Lilly and Company |
2023-07-31 | PHASE1 |
| NCT05990374 | UNKNOWN | Diabetes |
Nanjing First Hospital, Nanjing Medical University |
2023-08-01 | |
| NCT05553093 | RECRUITING | Type 2 Diabetes Mellitus |
Nanjing First Hospital, Nanjing Medical University |
2022-03-15 | PHASE4 |
| NCT04166773 | COMPLETED | Nonalcoholic Steatohepatitis |
Eli Lilly and Company |
2019-11-19 | PHASE2 |
| NCT05706506 | COMPLETED | Type 2 Diabetes; Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2023-03-08 | PHASE4 |
| NCT05810597 | COMPLETED | Healthy |
Eli Lilly and Company |
2023-04-03 | PHASE1 |
| NCT04844918 | COMPLETED | Obesity |
Eli Lilly and Company |
2021-05-10 | PHASE3 |
| NCT05582096 | COMPLETED | Overweight; Obesity |
Eli Lilly and Company |
2022-11-11 | PHASE1 |
| NCT04660643 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2021-03-29 | PHASE3 |
| NCT04657016 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2021-03-29 | PHASE3 |
| NCT04657003 | COMPLETED | Type 2 Diabetes; Overweight; Obesity |
Eli Lilly and Company |
2021-03-29 | PHASE3 |
| NCT05024032 | COMPLETED | Obesity; Overweight; Metabolism and Nutrition Disorder |
Eli Lilly and Company |
2021-09-01 | PHASE3 |
| NCT04311411 | COMPLETED | Obesity; Overweight |
Eli Lilly and Company |
2020-08-24 | PHASE1 |
| NCT04537923 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2020-10-19 | PHASE3 |
| NCT04081337 | COMPLETED | Obesity |
Eli Lilly and Company |
2020-07-09 | PHASE1 |
| NCT04184622 | COMPLETED | Overweight; Obesity |
Eli Lilly and Company |
2019-12-04 | PHASE3 |
| NCT04050553 | COMPLETED | Diabetes Mellitus, Type 2; Hypoglycemia |
Eli Lilly and Company |
2020-02-24 | PHASE1 |
| NCT04093752 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2019-12-09 | PHASE3 |
| NCT04235959 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2020-10-21 | PHASE1 |
| NCT03951753 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2019-06-28 | PHASE1 |
| NCT03861052 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2019-05-07 | PHASE3 |
| NCT04172987 | COMPLETED | Healthy |
Eli Lilly and Company |
2020-02-26 | PHASE1 |
| NCT03987919 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2019-07-30 | PHASE3 |
| NCT03861039 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2019-03-30 | PHASE3 |
| NCT03730662 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2018-11-20 | PHASE3 |
| NCT04407234 | COMPLETED | Overweight; Obesity; Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2020-09-15 | PHASE1 |
| NCT04039503 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2019-08-30 | PHASE3 |
| NCT03882970 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2019-04-01 | PHASE3 |
| NCT03954834 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2019-06-03 | PHASE3 |
| NCT04311424 | COMPLETED | Healthy |
Eli Lilly and Company |
2020-07-28 | PHASE1 |
| NCT03940742 | COMPLETED | Hepatic Insufficiency |
Eli Lilly and Company |
2019-07-22 | PHASE1 |
| NCT04050670 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-09-13 | PHASE1 |
| NCT04004988 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-08-19 | PHASE1 |
| NCT03482024 | COMPLETED | Renal Insufficiency; End Stage Renal Disease |
Eli Lilly and Company |
2018-03-30 | PHASE1 |
| NCT03375463 | COMPLETED | Healthy |
Eli Lilly and Company |
2017-12-19 | PHASE1 |
| NCT03131687 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2017-05-24 | PHASE2 |
| NCT03322631 | COMPLETED | Type 2 Diabetes Mellitus |
Eli Lilly and Company |
2017-11-15 | PHASE1 |
| NCT03311724 | COMPLETED | Type 2 Diabetes |
Eli Lilly and Company |
2017-10-19 | PHASE2 |
| NCT02759107 | COMPLETED | Healthy; Type 2 Diabetes Mellitus (T2DM) |
Eli Lilly and Company |
2016-05-11 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-07-28)
Check the
Tirzepatide (LY3298176) sodium
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Tirzepatide (LY3298176) sodium Solubility in DMSO
- Tirzepatide (LY3298176) sodium Stock Solution
- Tirzepatide (LY3298176) sodium Storage
- Tirzepatide (LY3298176) sodium Stability
- Tirzepatide (LY3298176) sodium Molecular Weight
- Tirzepatide (LY3298176) sodium CAS Number
- Tirzepatide (LY3298176) sodium Chemical Structure (2D and 3D)
- Tirzepatide (LY3298176) sodium SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.